• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

性别与癌症免疫疗法:当前的认识与挑战

Sex and cancer immunotherapy: Current understanding and challenges.

作者信息

Pala Laura, De Pas Tommaso, Catania Chiara, Giaccone Giuseppe, Mantovani Alberto, Minucci Saverio, Viale Giuseppe, Gelber Richard D, Conforti Fabio

机构信息

Division of Melanoma, Sarcomas and Rare Tumors, European Institute of Oncology, Milan, Italy.

Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.

出版信息

Cancer Cell. 2022 Jul 11;40(7):695-700. doi: 10.1016/j.ccell.2022.06.005. Epub 2022 Jun 23.

DOI:10.1016/j.ccell.2022.06.005
PMID:35750053
Abstract

Recent evidence highlights patients' sex relevance in antitumor immune response through a complex interaction-among hormones, genes, behaviors, and the microbiome-that affects both innate and adaptive immune functions, as well as immune evasion mechanisms. These complex interactions ultimately influence the efficacy and toxicity of immune checkpoint inhibitors in solid tumors.

摘要

最近的证据突显了患者性别在抗肿瘤免疫反应中的相关性,这是通过激素、基因、行为和微生物群之间的复杂相互作用实现的,这些相互作用会影响先天性和适应性免疫功能以及免疫逃逸机制。这些复杂的相互作用最终会影响实体瘤中免疫检查点抑制剂的疗效和毒性。

相似文献

1
Sex and cancer immunotherapy: Current understanding and challenges.性别与癌症免疫疗法:当前的认识与挑战
Cancer Cell. 2022 Jul 11;40(7):695-700. doi: 10.1016/j.ccell.2022.06.005. Epub 2022 Jun 23.
2
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.利用抗血管生成药物提高抗肿瘤免疫:机制见解、当前进展和临床挑战。
Cancer Commun (Lond). 2021 Sep;41(9):830-850. doi: 10.1002/cac2.12183. Epub 2021 Jun 17.
3
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.头颈部癌的免疫治疗:超越检查点阻断。
J Dent Res. 2019 Sep;98(10):1073-1080. doi: 10.1177/0022034519864112. Epub 2019 Jul 24.
4
Targeting innate sensing in the tumor microenvironment to improve immunotherapy.靶向肿瘤微环境中的先天感应以改善免疫疗法。
Cell Mol Immunol. 2020 Jan;17(1):13-26. doi: 10.1038/s41423-019-0341-y. Epub 2019 Dec 16.
5
Gut microbiome and cancer immunotherapy.肠道微生物组与癌症免疫治疗。
Cancer Lett. 2019 Apr 10;447:41-47. doi: 10.1016/j.canlet.2019.01.015. Epub 2019 Jan 23.
6
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.癌症免疫疗法的疗效与患者性别:系统评价和荟萃分析。
Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16.
7
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.CD47-SIRPα 免疫检查点在肿瘤免疫逃逸和固有免疫治疗中的作用。
Life Sci. 2021 May 15;273:119150. doi: 10.1016/j.lfs.2021.119150. Epub 2021 Mar 1.
8
A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.癌症中新的生物学三角:肠道微生物群、免疫检查点抑制剂和抗生素。
Clin Transl Oncol. 2021 Dec;23(12):2415-2430. doi: 10.1007/s12094-021-02659-w. Epub 2021 Jun 14.
9
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.自然杀伤细胞:癌症免疫治疗成功的关键。
Front Immunol. 2021 Apr 28;12:679117. doi: 10.3389/fimmu.2021.679117. eCollection 2021.
10
Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer.实体瘤中的免疫疗法与肠道微生物群:相关性——特别提及结直肠癌
Cancers (Basel). 2020 Dec 25;13(1):43. doi: 10.3390/cancers13010043.

引用本文的文献

1
PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis.前蛋白转化酶枯草溶菌素9(PCSK9)抑制剂与肿瘤发生风险降低的潜在关联,尤其是在女性中:一项荟萃分析
Pharmaceuticals (Basel). 2025 Jul 24;18(8):1095. doi: 10.3390/ph18081095.
2
Immunosenescence and cancer: molecular hallmarks, tumor microenvironment remodeling, and age-specific immunotherapy challenges.免疫衰老与癌症:分子特征、肿瘤微环境重塑及特定年龄的免疫治疗挑战
J Hematol Oncol. 2025 Aug 22;18(1):81. doi: 10.1186/s13045-025-01735-w.
3
Risk factors of immune checkpoint inhibitor-related cardiotoxicity: a scoping review.
免疫检查点抑制剂相关心脏毒性的危险因素:一项范围综述
Oncologist. 2025 Jul 4;30(7). doi: 10.1093/oncolo/oyaf187.
4
Twenty-year survival outcomes after multipeptide vaccination for resected high-risk melanoma: A post-hoc analysis of a randomized clinical trial.多肽疫苗接种后切除的高危黑色素瘤患者的20年生存结局:一项随机临床试验的事后分析
Int J Cancer. 2025 Nov 1;157(9):1912-1923. doi: 10.1002/ijc.70006. Epub 2025 Jun 19.
5
Sex bias in tumor immunity: insights from immune cells.肿瘤免疫中的性别偏见:来自免疫细胞的见解
Theranostics. 2025 Mar 31;15(11):5045-5072. doi: 10.7150/thno.106465. eCollection 2025.
6
Steroid hormones as modulators of anti-tumoural immunity.类固醇激素作为抗肿瘤免疫的调节剂。
Nat Rev Endocrinol. 2025 Jun;21(6):331-343. doi: 10.1038/s41574-025-01102-2. Epub 2025 Mar 24.
7
Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis.接受免疫检查点抑制剂治疗的癌症患者免疫相关不良事件严重程度及发病时间的预测因素:一项回顾性分析
Front Immunol. 2025 Feb 18;16:1508512. doi: 10.3389/fimmu.2025.1508512. eCollection 2025.
8
Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.一线免疫检查点抑制剂联合化疗与单纯化疗治疗晚期胃癌的疗效、安全性及生物标志物分析:一项多中心回顾性队列研究
BMC Med. 2024 Dec 18;22(1):585. doi: 10.1186/s12916-024-03801-5.
9
Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.体细胞突变景观揭示了癌症免疫治疗结果和性别差异的突变特征和显著突变基因。
Front Immunol. 2024 Nov 1;15:1423796. doi: 10.3389/fimmu.2024.1423796. eCollection 2024.
10
A multidimensional analysis of the impact of obesity on immune checkpoint inhibitor therapy efficacy.肥胖对免疫检查点抑制剂治疗疗效影响的多维度分析。
Cancer Cell Int. 2024 Oct 29;24(1):358. doi: 10.1186/s12935-024-03532-w.